Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed
Highlights
– A 2025 systematic review and meta-analysis (Katsuragawa et al., Lancet Diabetes Endocrinol) pooled data from 24 observational cohorts (6,621 patients) and found that patients with unsuppressed renin after medical therapy for primary aldosteronism had lower cardiovascular event rates (pooled HR 0.43, 95% CI 0.23–0.80).
– The cardiovascular benefit was more pronounced with longer follow-up (≥5 years; pooled HR 0.33, 95% CI 0.19–0.57), while associations with renal outcomes were null and data on mortality were sparse.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.